Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23833808 | 0.98 | EPHX2 (0.46) | EPHX2EPHX1GRIN2DGRIN3BGRIN1 | |
| Nitric Acid SCHEMBL28246395 | 0.68 | NPC1 (0.46) | EPHX2EPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1200529 | 0.67 | GRIN2D (0.35) | EPHX2EPHX1GRIN2DGRIN3BGRIN1 | |
| Nitric Acid SCHEMBL27581626 | 0.67 | EPHX2 (0.39) | EPHX2EPHX1L3MBTL1ALDH1A1RAB9A | |
| SCHEMBL2365754 | 0.66 | GRIN2D (0.52) | EPHX2EPHX1GRIN2DGRIN3BGRIN1 | |
| Amantadine SCHEMBL21801809 | 0.65 | GRIN2D (0.59) | EPHX2EPHX1GRIN2DGRIN3BGRIN1 | |
| Amantadine SCHEMBL21801807 | 0.65 | LMNA (0.64) | EPHX2EPHX1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL18884208 | 0.65 | EPHX2 (0.73) | EPHX2EPHX1KMT2AJAK2ALDH1A1 | |
| SCHEMBL3069160 | 0.65 | EPHX2 (1.00) | EPHX2EPHX1L3MBTL1JAK2ALDH1A1 | |
| SCHEMBL3073973 | 0.65 | EPHX2 (1.00) | EPHX2EPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710845-A2 | METHODS FOR TREATING AUTISM SPECTRUM DISORDER | The General Hospital Corporation (US) | 2026-03-18 | — | — | EP | claimed |
| US-20240130675-A1 | Methods for Treating Autism Spectrum Disorder | THE GENERAL HOSPITAL CORPORATION | 2024-04-25 | — | — | US | claimed |
| EP-4288150-A1 | METHODS FOR TREATING AUTISM SPECTRUM DISORDER | The General Hospital Corporation (US) | 2023-12-13 | — | — | EP | claimed |
| CN-117202846-A | Method of treatment of autism spectrum disorders | 总医院公司 | 2023-12-08 | — | — | CN | claimed |
| US-20230218548-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | EUMENTIS THERAPEUTICS, INC. | 2023-07-13 | — | — | US | claimed |
| EP-4121403-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | Eumentis Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | claimed |
| WO-2022169822-A1 | METHODS FOR TREATING AUTISM SPECTRUM DISORDER | THE GENERAL HOSPITAL CORPORATION (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2021231582-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF NEGATIVE SYMPTOMS AND COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA | EUMENTIS THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | claimed |
| WO-2021188864-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | EUMENTIS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | claimed |
| EP-4710845-A2 | METHODS FOR TREATING AUTISM SPECTRUM DISORDER | The General Hospital Corporation (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20240130675-A1 | Methods for Treating Autism Spectrum Disorder | THE GENERAL HOSPITAL CORPORATION | 2024-04-25 | — | — | US | disclosed |
| EP-4288150-A1 | METHODS FOR TREATING AUTISM SPECTRUM DISORDER | The General Hospital Corporation (US) | 2023-12-13 | — | — | EP | disclosed |
| CN-117202846-A | Method of treatment of autism spectrum disorders | 总医院公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20230218548-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | EUMENTIS THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021188864-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | EUMENTIS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188864-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | EUMENTIS THERAPEUTICS, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20090234021-A1 | Treatment of Demyelinating Conditions | LIPTON STUART A | 2009-09-17 | — | — | US | disclosed |
| EP-1613155-A2 | TREATMENT OF DEMYELINATING CONDITIONS | Neuromolecular Inc. (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050065219-A1 | Treatment of demyelinating conditions | NEUROMOLECULAR, INC. | 2005-03-24 | — | — | US | disclosed |
| WO-2004087073-A2 | TREATMENT OF DEMYELINATING CONDITIONS | NEUROMOLECULAR, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234021-A1 | Treatment of Demyelinating Conditions | PMP22, MAG, MYT1 | EPHX2 1332/4885EPHX1 944/4885GRIN2D 1269/4885 |
| US-20050065219-A1 | Treatment of demyelinating conditions | PMP22, MAG, MYT1 | EPHX2 1332/4885EPHX1 944/4885GRIN2D 1269/4885 |
| US-20240130675-A1 | Methods for Treating Autism Spectrum Disorder | GRIN2A, GRIN1, GRM2 | EPHX2 1871/4885EPHX1 1440/4885GRIN2D 15/4885 |
| US-20230218548-A1 | NITRO-AMINOADAMANTANE COMPOUNDS FOR THE TREATMENT OF BETACORONAVIRUS INFECTIONS | ACE2, ACE, MME | EPHX2 2171/4885EPHX1 1123/4885GRIN2D 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.